1. Home
  2. NABL vs EWTX Comparison

NABL vs EWTX Comparison

Compare NABL & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NABL
  • EWTX
  • Stock Information
  • Founded
  • NABL 2000
  • EWTX 2017
  • Country
  • NABL United States
  • EWTX United States
  • Employees
  • NABL N/A
  • EWTX N/A
  • Industry
  • NABL Computer Software: Prepackaged Software
  • EWTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NABL Technology
  • EWTX Health Care
  • Exchange
  • NABL Nasdaq
  • EWTX Nasdaq
  • Market Cap
  • NABL 1.2B
  • EWTX 1.5B
  • IPO Year
  • NABL N/A
  • EWTX 2021
  • Fundamental
  • Price
  • NABL $8.23
  • EWTX $14.12
  • Analyst Decision
  • NABL Buy
  • EWTX Buy
  • Analyst Count
  • NABL 4
  • EWTX 9
  • Target Price
  • NABL $9.38
  • EWTX $39.89
  • AVG Volume (30 Days)
  • NABL 939.1K
  • EWTX 571.1K
  • Earning Date
  • NABL 08-07-2025
  • EWTX 08-07-2025
  • Dividend Yield
  • NABL N/A
  • EWTX N/A
  • EPS Growth
  • NABL N/A
  • EWTX N/A
  • EPS
  • NABL 0.08
  • EWTX N/A
  • Revenue
  • NABL $470,595,000.00
  • EWTX N/A
  • Revenue This Year
  • NABL $8.35
  • EWTX N/A
  • Revenue Next Year
  • NABL $8.84
  • EWTX N/A
  • P/E Ratio
  • NABL $101.26
  • EWTX N/A
  • Revenue Growth
  • NABL 7.98
  • EWTX N/A
  • 52 Week Low
  • NABL $6.07
  • EWTX $10.60
  • 52 Week High
  • NABL $14.15
  • EWTX $38.12
  • Technical
  • Relative Strength Index (RSI)
  • NABL 57.60
  • EWTX 52.19
  • Support Level
  • NABL $7.66
  • EWTX $13.34
  • Resistance Level
  • NABL $8.18
  • EWTX $14.66
  • Average True Range (ATR)
  • NABL 0.20
  • EWTX 0.59
  • MACD
  • NABL 0.01
  • EWTX 0.15
  • Stochastic Oscillator
  • NABL 72.61
  • EWTX 72.86

About NABL N-able Inc.

N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Share on Social Networks: